BCL2 and cancer: Abnormally increased expression of pro-survival BCL-2 proteins or decreased levels of the pro-apoptotic BCL-2 family members have been implicated in the development and therapy resistance of a variety of cancers, particularly leukaemias and lymphomas [6].